The fundamental importance of Integration for Ketamine therapy

Ketamine assisted psychotherapy – fundamental to your Ketamine therapy

Ketamine integration therapy combines ketamine treatment with psychotherapy to help patients achieve deeper healing and lasting mental health improvements. At Libertas Mind, personalized support before and after treatment helps maximize long-term benefits.

Discover Spravato, A Specialized Nasal Spray for Resistant Depression

Discover Spravato, A Specialized Nasal Spray for Resistant Depression

Spravato (esketamine) is an FDA-approved nasal spray for adults with treatment-resistant depression who haven’t responded to traditional antidepressants. Administered under medical supervision, it offers a fast-acting treatment option that may provide long-lasting symptom relief.

Finding Calm: Your Guide to Anxiety Treatment in Clifton Park, NY

Finding Calm Your Guide to Anxiety Treatment in Clifton Park

Anxiety can affect every aspect of daily life, but effective treatments like therapy, medication, lifestyle changes, and innovative options such as ketamine therapy may help. If you’re in Clifton Park, NY, connecting with a qualified mental health professional is the first step toward finding the right treatment and improving your well-being.

The emerging role of esketamine for chronic pain

Since the FDA approved esketamine (Spravato) for treatment-resistant depression and depressive symptoms in adults with MDD who had acute suicidal ideation in 2019, new information is emerging of it’s effect in patients with comorbid chronic pain and depression.

Spravato therapy

After nearly 2 decades of research, the benefits of ketamine for depression are universally recognized. As unique and transformative as ketamine is, it remains an out-of-pocket treatment and not covered by insurance.

Achieve Superior Results today for Your Depression with Spravato Nasal Spray

The STAR*D trial demonstrated that the more antidepressants a patient trial’s the less likely they are to respond overall. By the point a patient tries 3 antidepressant’s, the remission rate is only about 15% with another treatment trial. Of the patients who respond remit at level 3 of 4, 60-70% will relapse within 6 months.